Advertisement
GH or ISRG or NTRA
Which Stock Would AI Choose? Guardant Health (GH) vs. Intuitive Surgical (ISRG) vs. Natera (NTRA) Stock Comparison
Key Takeaways
- ISRG leads with a $162 billion market cap and profitability, boasting a 28% profit margin and strong Q1 2026 revenue growth of 23% year-over-year.
- GH delivers the strongest one-year return at 79%, driven by momentum in precision oncology diagnostics amid analyst optimism.
- NTRA shows steady revenue expansion to $2.31 billion trailing twelve months (TTM), with positive analyst coverage ahead of recent quarterly results.
- All three stocks operate in high-growth healthcare niches—diagnostics and medtech—with betas above 1.4, signaling elevated volatility relative to the market.
- ISRG edges year-to-date performance at 19%, while GH and NTRA trail at 14% and 10%, respectively, amid sector rotation.
Introduction
This stock comparison examines GH, ISRG, and NTRA, three leaders in innovative healthcare solutions. Guardant Health and Natera focus on precision diagnostics through liquid biopsy and cell-free DNA (cfDNA) testing, while Intuitive Surgical dominates robotic-assisted surgery. Investors and traders interested in medtech and biotech growth stocks—particularly those tracking procedure volumes, test adoption, and regulatory catalysts—will find value in assessing their relative performance, valuation sensitivities, and market positioning in the current environment.
GH Overview and Recent Performance
Guardant Health (GH) specializes in precision oncology via liquid biopsy tests that detect cancer through blood samples, aiding early detection and therapy selection. Shares have shown resilience in recent market activity, trading around the mid-$80s after a robust one-year gain of 79% from a 52-week low of $36.36. With a market cap of $11.6 billion, the company reported $982 million in TTM revenue but remains unprofitable with a -$3.32 EPS (earnings per share). Sentiment has been buoyed by analyst upgrades and real-world evidence supporting its tests, though volatility persists with a beta of 1.49, reflecting diagnostics sector dynamics.
ISRG Overview and Recent Performance
Intuitive Surgical (ISRG) pioneers robotic-assisted minimally invasive surgery with its da Vinci systems, generating recurring revenue from instruments and services. The stock, priced near $458 with a $162 billion market cap, leads year-to-date at 19% amid broader stability. Q1 2026 results highlighted $2.77 billion in revenue, up 23% year-over-year, underscoring procedure growth despite international procedure softness. Profitable with a PE ratio (price-to-earnings) of 55.56 and 28% margins, shares exhibit a beta of 1.51, influenced by high valuation scrutiny and competitive robotics landscape.
NTRA Overview and Recent Performance
Natera (NTRA) develops cfDNA tests for oncology, women's health, and organ health monitoring. Trading around $207 with a $29.6 billion market cap, it posted a 37% one-year return and 10% year-to-date amid revenue scaling to $2.31 billion TTM. Recent weeks featured analyst initiations with outperform ratings and anticipation for quarterly updates, though losses persist at -$1.51 EPS and a beta of 1.68 signals higher risk in the genetic testing space.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top 25 performers from over 351 AI trading bots that analyze thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies—from momentum and sector rotation to technical patterns and risk-managed swing trades—with performance metrics like annualized returns up to +163%, win rates of 51-88%, profit factors from 1.5 to 4.5, and profit-to-drawdown ratios exceeding 17 in some cases. Selected for current market conditions, they include virtual agents with customizable risk controls and brokerage-linked automation, catering to day traders, swing traders, and long-term investors. Explore Trending AI Robots to identify bots aligning with your style and enhance decision-making in dynamic markets.
Head-to-Head Comparison
GH and NTRA share diagnostics business models reliant on test volume growth and reimbursement, contrasting ISRG’s hybrid of system sales and high-margin consumables. Growth drivers include oncology demand for GH/NTRA and surgical procedure expansion for ISRG, with recent momentum favoring GH’s 79% one-year surge over NTRA’s 37% and ISRG’s 11%. Risk factors weigh heavier for unprofitable GH/NTRA (negative margins) versus ISRG’s stability, amplified by NTRA’s highest beta. Valuation sensitivity is acute for loss-makers GH/NTRA on price-to-sales multiples, while ISRG trades at a premium PE due to earnings power. Market sentiment tilts positive across the board, with trade-offs in volatility versus scale.
Tickeron AI Verdict
Tickeron’s AI would likely favor ISRG in the current environment, given its trend consistency, profitability, Q1 catalysts, and dominant positioning amid healthcare innovation. While GH and NTRA offer higher momentum potential, ISRG’s relative stability and procedure growth provide a probabilistic edge for trend-following models.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GH’s FA Score shows that 0 FA rating(s) are green whileISRG’s FA Score has 0 green FA rating(s), and NTRA’s FA Score reflects 0 green FA rating(s).
- GH’s FA Score: 0 green, 5 red.
- ISRG’s FA Score: 0 green, 5 red.
- NTRA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GH’s TA Score shows that 5 TA indicator(s) are bullish while ISRG’s TA Score has 4 bullish TA indicator(s), and NTRA’s TA Score reflects 5 bullish TA indicator(s).
- GH’s TA Score: 5 bullish, 4 bearish.
- ISRG’s TA Score: 4 bullish, 5 bearish.
- NTRA’s TA Score: 5 bullish, 4 bearish.
Price Growth
GH (@Medical Specialties) experienced а +11.64% price change this week, while ISRG (@Pharmaceuticals: Other) price change was -4.32% , and NTRA (@Medical Specialties) price fluctuated -1.24% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.63%. For the same industry, the average monthly price growth was +0.72%, and the average quarterly price growth was -7.39%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.11%. For the same industry, the average monthly price growth was +0.69%, and the average quarterly price growth was +21.23%.
Reported Earning Dates
GH is expected to report earnings on Jul 30, 2026.
ISRG is expected to report earnings on Jul 16, 2026.
NTRA is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical Specialties (-0.63% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-1.11% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| GH | ISRG | NTRA | |
| Capitalization | 13.3B | 153B | 29.2B |
| EBITDA | -390.98M | 3.95B | -227.7M |
| Gain YTD | -2.154 | -23.746 | -10.860 |
| P/E Ratio | N/A | 52.48 | N/A |
| Revenue | 1.08B | 10.6B | 2.5B |
| Total Cash | 1.1B | 4.52B | 1.09B |
| Total Debt | 1.71B | 87M | 240M |
GH | ISRG | NTRA | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 67 | 19 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | 87 Overvalued | 59 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 54 | 49 | |
SMR RATING 1..100 | 100 | 50 | 94 | |
PRICE GROWTH RATING 1..100 | 41 | 64 | 53 | |
P/E GROWTH RATING 1..100 | 100 | 86 | 100 | |
SEASONALITY SCORE 1..100 | 90 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (59) in the Biotechnology industry is in the same range as GH (75) in the Medical Or Nursing Services industry, and is in the same range as ISRG (87) in the Medical Specialties industry. This means that NTRA's stock grew similarly to GH’s and similarly to ISRG’s over the last 12 months.
NTRA's Profit vs Risk Rating (49) in the Biotechnology industry is in the same range as ISRG (54) in the Medical Specialties industry, and is somewhat better than the same rating for GH (100) in the Medical Or Nursing Services industry. This means that NTRA's stock grew similarly to ISRG’s and somewhat faster than GH’s over the last 12 months.
ISRG's SMR Rating (50) in the Medical Specialties industry is somewhat better than the same rating for NTRA (94) in the Biotechnology industry, and is somewhat better than the same rating for GH (100) in the Medical Or Nursing Services industry. This means that ISRG's stock grew somewhat faster than NTRA’s and somewhat faster than GH’s over the last 12 months.
GH's Price Growth Rating (41) in the Medical Or Nursing Services industry is in the same range as NTRA (53) in the Biotechnology industry, and is in the same range as ISRG (64) in the Medical Specialties industry. This means that GH's stock grew similarly to NTRA’s and similarly to ISRG’s over the last 12 months.
ISRG's P/E Growth Rating (86) in the Medical Specialties industry is in the same range as GH (100) in the Medical Or Nursing Services industry, and is in the same range as NTRA (100) in the Biotechnology industry. This means that ISRG's stock grew similarly to GH’s and similarly to NTRA’s over the last 12 months.
| GH | ISRG | NTRA | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 63% | 1 day ago 68% | N/A |
| Stochastic ODDS (%) | 1 day ago 78% | 1 day ago 72% | 1 day ago 76% |
| Momentum ODDS (%) | 1 day ago 74% | 1 day ago 58% | 1 day ago 78% |
| MACD ODDS (%) | 1 day ago 81% | 1 day ago 71% | 1 day ago 76% |
| TrendWeek ODDS (%) | 1 day ago 79% | 1 day ago 61% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 68% | 1 day ago 82% |
| Advances ODDS (%) | 1 day ago 79% | 7 days ago 68% | 1 day ago 80% |
| Declines ODDS (%) | 16 days ago 85% | 3 days ago 57% | 15 days ago 78% |
| BollingerBands ODDS (%) | 1 day ago 88% | 1 day ago 63% | 1 day ago 72% |
| Aroon ODDS (%) | N/A | 1 day ago 57% | 1 day ago 84% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JPUS | 135.85 | -0.01 | N/A |
| JPMorgan Diversified Return US Eq ETF | |||
| PMSE | 26.05 | N/A | N/A |
| PGIM S&P 500 Max Buffer ETF - September | |||
| BOAT | 42.53 | -0.03 | -0.07% |
| SonicShares™ Global Shipping ETF | |||
| APXM | 31.55 | -0.03 | -0.08% |
| FT Vest U.S. Equity Max Buffr ETF - Apr | |||
| FV | 69.59 | -0.19 | -0.27% |
| First Trust Dorsey Wright Focus 5 ETF | |||
GH and
Correlation & Price change
A.I.dvisor indicates that over the last year, GH has been loosely correlated with NTRA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if GH jumps, then NTRA could also see price increases.
ISRG and
Correlation & Price change
A.I.dvisor indicates that over the last year, ISRG has been closely correlated with BSX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if ISRG jumps, then BSX could also see price increases.
| Ticker / NAME | Correlation To ISRG | 1D Price Change % | ||
|---|---|---|---|---|
| ISRG | 100% | +2.81% | ||
| BSX - ISRG | 73% Closely correlated | +1.37% | ||
| SYK - ISRG | 64% Loosely correlated | +4.20% | ||
| NTRA - ISRG | 54% Loosely correlated | +2.55% | ||
| GKOS - ISRG | 51% Loosely correlated | +0.73% | ||
| PODD - ISRG | 49% Loosely correlated | +2.71% | ||
More | ||||